Anti-CD8 alpha antibody (Ab4055)
CD8a, MAL, CD8A, T-cell surface glycoprotein CD8 alpha chain, T-lymphocyte differentiation antigen T8/Leu-2
详细信息
特异性
From Mar 2024, QC testing of replenishment batches of this polyclonal changed. All tested and expected application and reactive species combinations are still covered by our Abcam product promise. However, we no longer test all applications. For more information on a specific batch, please contact our Scientific Support who will be happy to help. You may also be interested in our alternative recombinant antibody, ab178089.
背景信息
Product Specifications Anti-CD8 alpha antibody (ab4055) is a rabbit polyclonal antibody and is validated for use in IHC-P in human samples. Anti-CD8 alpha antibody (ab4055) specifically detects CD8 alpha (UniProt ID: P01732; Molecular weight: 24kDa) and is sold in 500 µL and 1 mL selling sizes. Quality and Validation Abcam's high quality validation processes ensure Anti-CD8 alpha antibody (ab4055) has high sensitivity and specificity. Anti-CD8 alpha antibody (ab4055) has been cited over 184 times in peer reviewed journals and is trusted by the scientific community. Anti-CD8 alpha antibody (ab4055) has 14 independent reviews from customers. Target Information CD8 alpha is a transmembrane glycoprotein that serves as a co-receptor for the T-cell receptor (TCR), primarily found on cytotoxic T cells. It plays a crucial role in T cell signaling and cytotoxic activity by binding to MHC class I molecules, aiding in the immune response against infected or malignant cells. CD8 alpha is associated with several diseases, particularly those involving immune system dysfunction.
文献引用 (206)
Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms.
增强胃癌免疫疗法：来自多组学分析和光动力化学疗法纳米平台创新的见解。
Loss of MicroRNA-29b promotes DNMT3b-mediated STING downregulation to attenuate radiotherapy-induced antitumor immunity in KRAS-mutated colorectal cancer.
MicroRNA-29b 的缺失促进 DNMT3b 介导的 STING 下调，从而减弱 KRAS 突变型结直肠癌中放射治疗诱导的抗肿瘤免疫。
Therapeutic targets established in adult ulcerative colitis exhibit correlations with disease severity and pathological relevance in pediatric pouchitis.
成人溃疡性结肠炎中确定的治疗靶点与儿童回肠贮袋炎的疾病严重程度和病理相关性存在相关性。
CXCL12-mediated T cell infiltration drives breast cancer metastasis.
CXCL12介导的T细胞浸润驱动乳腺癌转移。
Combined assessment of ERO1A expression and CD163+ tumor-associated macrophage infiltration is superior to traditional assessment methods in predicting clear cell renal cell carcinoma prognosis
联合评估 ERO1A 表达和 CD163+ 肿瘤相关巨噬细胞浸润在预测透明细胞肾细胞癌预后方面优于传统评估方法。
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients.
Tebentafusp 可诱导葡萄膜黑色素瘤患者产生由细胞毒性 T 细胞驱动的靶向皮肤免疫反应
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.
帕博利珠单抗联合瘤内注射诺维梭菌-NT治疗晚期实体瘤患者的Ib期研究。
CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer.
CHK1 抑制通过 ARID1A 缺陷型结直肠癌的抗肿瘤免疫增强放射治疗的疗效
Transplantation of engineered vascularized lymphatic tissue using LEC and in vivo AV loop model to enhance lymphangiogenesis and restore lymphatic drainage in a lymphadenectomy rat model.
利用 LEC 和体内 AV 环模型移植工程化血管化淋巴组织，以增强淋巴管生成并恢复淋巴引流，用于淋巴结切除大鼠模型
MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma.
MITF、TFEB 和 TFE3 驱动黑色素瘤中不同的适应性基因表达程序和免疫浸润。
- 1
- 2
- 3
- 4
- 5
- 6
- 21